PartnershipMay 18, 2026, 07:01 AM
Regeneron partners with Parabilis for $2.3B peptide platform deal
AI Summary
Regeneron Pharmaceuticals announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates using Parabilis' Helicon peptide platform, specifically Antibody-Helicon Conjugates (AHCs). This partnership aims to target challenging and historically "undruggable" intracellular proteins. Regeneron will provide $125 million to Parabilis, consisting of a $50 million upfront payment and a $75 million equity commitment, with potential for up to $2.2 billion in additional milestone payments and tiered royalties.
Key Highlights
- Regeneron to provide $125M to Parabilis ($50M upfront, $75M equity commitment).
- Parabilis eligible for up to approximately $2.2B in additional milestone payments.
- Parabilis to receive tiered royalties up to low double-digits on net sales.
- Collaboration focuses on Antibody-Helicon Conjugates (AHCs) for undruggable targets.
- Agreement covers five initial targets, with options for more.
- Regeneron will handle development, manufacturing, and worldwide commercialization.
Price Impact
More from REGN